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Abstract
AIM: To evaluate metabolic control and health-related 
quality of life (HRQOL) in a type 1 diabetes mellitus 
(T1DM) population. 
METHODS: As part of a prospective cohort study, 283 
T1DM patients treated with various insulin treatment 
modalities including multiple daily injections (MDI) and 
continuous subcutaneous insulin infusion (CSII) were 
examined annually. HRQOL was measured using the 
SF-36 and EuroQol questionnaires. Data regarding 
HRQOL, glycaemic and metabolic control from base-
line and follow-up measures in 2002 and 2010 were 
analysed. Linear mixed models were used to calculate 
estimated values and differences between the three 
moments in time and the three treatment modalities.
RESULTS: Significant changes [mean Δ (95%CI)] in 
body mass index [2.4 kg/m2 (1.0, 3.8)], systolic blood 
pressure [-6.4 mmHg (-11.4, -1.3)] and EuroQol-VAS 
[-7.3 (-11.4, -3.3)] were observed over time. In 2010, 
168 patients were lost to follow-up. Regarding mode of 
therapy, 52 patients remained on MDI, 28 remained on 
CSII, and 33 patients switched from MDI to CSII during 
follow-up. Among patients on MDI, HRQOL decreased 
significantly over time: mental component summary 
[-9.8 (-16.3, -3.2)], physical component summary [-8.6 
(-15.3, -1.8)] and EuroQol-VAS [-8.1 (-14.0, -2.3)], P  < 
0.05 for all. For patients using CSII, the EuroQol-VAS 
decreased [-9.6 (-17.5, -1.7)]. None of the changes 
over time in HRQOL differed significantly with the 
changes over time within the other treatment groups.
CONCLUSION: No differences with respect to meta-
bolic and HRQOL parameters between the various insu-
lin treatment modalities were observed after 15 years 
of follow-up in T1DM patients.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Key words: Type 1 diabetes mellitus; Health-related 
quality of life; Glycaemic control; Insulin treatment; 
Multiple daily injections; Continuous subcutaneous in-
sulin infusion
Core tip: The results of this study demonstrate that 
over a period of 15 years, general health-related qual-
ity of life is almost stable among patients with type 1 
diabetes mellitus. In addition, no differences with re-
spect to metabolic control and general health-related 
quality of life were observed among type 1 diabetes 
mellitus patients treated with different insulin regimens 
(multiple daily injections or continuous subcutaneous 
insulin infusion).
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INTRODUCTION
Patients with type 1 diabetes mellitus (T1DM) require 
lifelong daily insulin to compensate for an absolute en-
dogenous insulin shortage. In many patients, it is possible 
to achieve adequate or even tight glycaemic control and 
delay the onset and progression of  micro- and macrovas-
cular complications with intensive insulin therapy[1]. At 
present, multiple daily injections (MDI) and continuous 
subcutaneous insulin infusion (CSII) are the most com-
mon forms of  insulin administration in T1DM. 
It is likely that T1DM and its therapy impact health-
related quality of  life (HRQOL)[2]. Previous studies have 
underlined the importance of  this association by reveal-
ing a negative association between HRQOL and diabe-
tes prognosis[3-5]. In T1DM, a relevant deterioration of  
HRQOL and glycaemic control during the disease course 
has been reported[6,7]. In contrast, reports have also found 
no association between duration of  diabetes and scores 
on quality of  life scales[8,9]. In addition to diabetes dura-
tion and clinical and metabolic characteristics, such as 
body mass index (BMI), the presence of  macrovascular 
complications, hyperglycaemic complaints and personal 
characteristics influence HRQOL. In addition, insulin 
treatment with CSII is thought to have a positive effect 
on HRQOL compared with MDI[2,10,11].
The aim of  the present analysis was to assess long-
term metabolic control and HRQOL in T1DM patients 
treated with various therapy modes. Furthermore, we 
aimed to investigate whether mode of  therapy (MDI or 
CSII) influences long-term clinical and HRQOL param-
eters in T1DM patients. 
MATERIALS AND METHODS
Study design and population
The study was designed as a prospective, cohort study 
to investigate several disease factors, including oxidative 
stress and HRQOL, in T1DM. The full study design has 
been published in detail previously[12]. In brief, from Janu-
ary 1995 to January 1996, consecutive visiting T1DM 
patients treated at the diabetes outpatient clinic of  the 
Weezenlanden Hospital (currently Isala), Zwolle, The 
Netherlands, were invited to participate. T1DM was de-
fined as the initiation of  insulin therapy within 6 months 
after the first signs of  diabetes and before the age of  30 
years or the absence of  C-peptide secretion. In total, 293 
patients agreed to participate. The main scope was to as-
sess patients treated with MDI or CSII or patients switch-
ing from MDI to CSII during the study period. Patients 
who switched from CSII to MDI and back (n = 3) or 
from CSII to continuous intraperitoneal insulin infusion (n 
= 8) or underwent a pancreas and kidney transplantation 
(n = 1) were excluded from analysis. 
Measurement of clinical data and HRQOL
At baseline, a trained physician examined all patients 
according to a standardised protocol. Data concerning 
demographics, mode of  therapy, height, weight, blood 
pressure and several laboratory measurements were col-
lected. We adjusted the eGFR MDRD values for dif-
ferences using the conventional Jaffe creatinine method 
before 2007 and the isotope-dilution mass spectrometry-
traceable enzymatic creatinine method after 2007. 
HRQOL was assessed annually from 1995 to 2001, and 
these results were reported previously[12]. From 2001 on-
wards, HRQOL was assessed in 2002 and 2010. HRQOL 
was assessed using the SF-36 and EuroQoL. The SF-36 
is a widely used, self-administered generic questionnaire 
with 36 items involving 8 subscales: physical functioning, 
role limitations due to physical problems, bodily pain, 
general health perception, vitality, social functioning, 
role limitations due to emotional problems, and men-
tal health. Scale scores range from 0 to 100, and higher 
scores indicate better HRQOL. In addition, a physical 
and mental component summary (PCS and MCS) score 
can be determined[13]. The EuroQol is a generic measure 
developed by researchers from 5 European countries, 
including The Netherlands[14]. The questionnaire has 2 
parts. The first part consists of  5 items covering the areas 
of  mobility, self-care, usual activities, pain or discomfort 
and anxiety or depression (EQ-5D). Each item has 3 lev-
els: no problems, some problems, or extreme problems. 
EQ-5D scores were converted to a single index value 
(ranging from 0 for the worst health state to 1 for the 
best health state) using a value set specific for the Dutch 
population[15]. The second part consists of  a visual ana-
logue scale (VAS) from which a single overall score for 
self-rated health status can be elicited ranging from 0 to 
100 (EQ-VAS). 
Ethical considerations
The study was performed in accordance with the Decla-
ration of  Helsinki. Informed consent was obtained from 
all patients, and the protocol was approved by the local 
medical ethics committee.
Statistical analysis
All analyses were performed using SPSS version 18.0 
(SPSS, Inc., Chicago, Il, United States). A (two-sided) 
P-value of  less than 0.05 was considered statistically sig-
nificant. Q-Q plots were used to determine whether the 
tested variable had a normal distribution. Where appro-
priate, paired parametric and non-parametric tests were 
used to compare outcomes between baseline and follow-
up measurements. Linear mixed models with Bonferroni 
correction were used to calculate estimated values and 
test differences among the 3 moments in time (1995, 
2002 and 2010) and between the 3 treatment modalities 
van Dijk PR et al . Follow-up of HRQOL in T1DM































































































































































































































































































































































































































































































































































































































































































































































































































































   






   






   






   
   





   






   
   





   
   




























































































































































































































   







    







   







   







   







   







   
























   







    







   







   







   







   







   



















































   















   







   


















   






   






   






   
   





   






   
   





   
   




















   






   






   






   
   





   






   
   





   
   




















   






   






   






   
   





   
   





   
   





   
   



















   






   






   






   
   





   






   
   





   
   




























   
   





   
   





   
   





   
   





   
   





   
   




   
   



















   






   







   






   
   





   
   





   
   





   
   












   






   






   
   





   
   





   
   





   
   





   
   



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































572 August 15, 2014|Volume 5|Issue 4|WJD|www.wjgnet.com
van Dijk PR et al . Follow-up of HRQOL in T1DM
presented in Table 3. In total, BMI increased (mean 
difference: 2.4 kg/m2, 95%CI: 1.0-3.8; P < 0.00) and 
systolic blood pressure decreased [-6.4 mmHg, 95%CI: 
-11.4-(-1.3); P = 0.01] during the follow-up period. 
The BMI increased significantly in the group of  
patients who switched from MDI to CSII (2.7 kg/m2; 
95%CI: 0.2-5.2; P = 0.03), and systolic blood pressure 
decreased exclusively among MDI users [-9.2 mmHg; 
95%CI: -16.4-(-2.0); P = 0.01]. In 2010, no differences 
were observed between the various treatment categories 
(i.e., MDI, CSII and from MDI to CSII) concerning clini-
cal parameters at the end of  the follow-up.
Long term follow-up-HRQOL
The observed course of  the summary scores for the 
SF-36 and the EuroQol are presented in Table 2. The 
mean values and estimated changes in HRQOL are pre-
sented in Table 4. In total, no changes in both SF-36 
component scores were observed. At baseline, patients 
administered MDI displayed the highest MCS. The 
SF-36 subscales for physical functioning [-8.3, 95%CI: 
-14.9-(-1.7)], social functioning [-8.9, 95%CI: -16.3-(-1.6)], 
role limitations due to emotional problems [-15.0, 95%CI: 
-27.0-(-3.0)] and vitality [-10.0, 95%CI: -18.4-(-1.7)] de-
creased significantly over time among patients on MDI. 
In addition, the MCS and PCS for patients administered 
MDI were significantly lower in 2010 compared with 
1995, with a mean difference of  -9.8 [95%CI: -16.3-(-3.2)] 
and -8.6 [95%CI: -15.3-(-1.8)], respectively. The subscale 
vitality (Δ = 12.0, P = 0.03) displayed a more significant 
decrease over time among patients using MDI compared 
with patients who switched from MDI to CSII, and a 
greater decrease was observed with the subscale role limi-
tations due to emotional problems in patients adminis-
tered MDI compared with CSII (Δ = 22.1, P < 0.01) and 
switchers (Δ = 18.0, P = 0.02). MCS and PCS did not 
differ between the treatment groups. 
The EuroQol-VAS decreased among all patients [-7.3; 
95%CI: -11.4-(-3.3); P = 0.001]. For patients using CSII or 
MDI throughout the follow-up period, the EuroQol-VAS 
decreased throughout the follow-up period to -8.1 [95%CI: 
-14.0-(-2.3)] and -9.6 [95%CI: -17.5-(-1.7)], respectively.
None of  the HRQOL component scores differed 
from baseline among the patients who switched from 
MDI to CSII throughout the study. No differences con-
cerning HRQOL parameters were observed between the 
various treatment categories in 2010.
DISCUSSION
This is the first study to describe the long-term natural 
course of  HRQOL among patients with T1DM treated 
with different insulin treatment modalities. In general, no 
relevant HRQOL changes were observed after a follow-
up of  15 years. Between the treatment modalities, no dif-
ferences with respect to metabolic and HRQOL param-
eters were observed during follow-up.
The approximately stable HRQOL reported in the 
current study is somewhat surprising given the natural 
decrease in HRQOL in an unselected population after 5 
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Table 3  Estimated changes in clinical parameters during follow-up
Clinical characteristics 1995 (A) 2002 (B) Difference (B-A) P -value 2010 (C) Difference (C-A) P -value
BMI (kg/m2)
   All   24.9 (24.2, 25.5)   26.2 (25.4, 27.1)  1.4 (0.14, 2.6) 0.02   27.2 (26.3, 28.2)   2.4 (1.0, 3.8) 0.00
   MDI   25.1 (24.2, 25.9)   25.9 (24.8, 27.1) 0.9 (-0.9, 2.6) 0.72   27.0 (25.5, 28.4)    1.9 (-0.1, 4.0) 0.06
   CSII   24.9 (23.9, 26.0)   27.2 (25.5, 28.8)   2.3 (-0.16, 4.7) 0.08   27.4 (25.5, 29.1)    2.5 (-0.2, 5.3) 0.08
   From MDI to CSII   24.6 (23.5, 25.7)   25.6 (24.1, 27.1)      -1.0 (-1.2, 3.2) 0.82   27.3 (25.6, 29.1)   2.7 (0.2, 5.2) 0.03
Systolic BP (mmHg)
   All     137.0 (133.8, 140.3)     128.0 (124.7, 131.2)   -9.1 (-14.7, -3.5) 0.00     130.7 (128.1, 133.3)      -6.4 (-11.4, -1.3) 0.01
   MDI     140.8 (136.1, 145.4)     131.7 (127.2, 136.3)    -9.1 (- 17.0, -1.2) 0.02     131.6 (127.8, 135.3)      -9.2 (-16.4, -2.0) 0.01
   CSII     138.5 (132.2, 144.8)     125.9 (119.5, 132.3) -12.6 (-23.6, -1.7) 0.02     131.1 (126.1, 136.1)     -7.4 (-17.2, 2.4) 0.21
   From MDI to CSII     131.8 (126.0, 137.7)     126.3 (120.6, 132.1)  -5.5 (-15.5, 4.5) 0.55     129.4 (124.8, 134.0)     -2.5 (-11.5, 6.6) 1.00
HbA1c (mmol/mol)
   All 8.0 (7.6, 8.3) 7.6 (7.4, 7.8)  -0.37 (-0.85, 0.10) 0.19 7.5 (7.3, 7.6)     -0.47 (-0.93, 0.00) 0.05
   MDI 7.6 (7.1, 8.1) 7.6 (7.3, 7.9)   -0.02 (-0.70, -0.66) 1.00 7.4 (7.1, 7.6)     -0.25 (-0.91, 0.42) 1.00
   CSII 8.3 (7.7, 9.0) 7.6 (7.2, 7.9)  -0.78 (-1.71, 0.14) 0.13 7.6 (7.2, 7.9)     -0.79 (-1.70, 0.12) 0.11
   From MDI to CSII 8.0 (7.3, 8.6) 7.6 (7.3, 8.0)  -0.31 (-1.16, 0.54) 1.00 7.6 (7.3, 7.9)     -0.37 (-1.20, 0.47) 0.87
Total cholesterol (mmol/L)
   All 4.8 (4.7, 5.0) 4.5 (4.3, 4.7)   -0.32 (-0.62, -0.01) 0.04 4.9 (4.7, 5.0)      0.04 (-0.25, 0.32) 1.00
   MDI 4.9 (4.6, 5.2) 4.6 (4.4, 4.9)  -0.27 (-0.70, 0.15) 0.38 4.9 (3.1, 6.7) -0.01 (-0.4, 0.4) 1.00
   CSII 5.1 (4.8, 5.4) 4.7 (4.3, 5.0)  -0.42 (-1.00, 0.17) 0.26 4.8 (2.4, 7.2)   -0.31 (-0.9, 0.24) 1.00
   From MDI to CSII 4.5 (4.2, 4.8) 4.2 (3.9, 4.5)  -0.26 (-0.79, 0.29) 0.77 4.9 (4.6, 5.2)    0.42 (-0.1, 0.93) 0.15
eGFR (MDRD; mL/min per 1.73 m2)
   All   88.3 (85.3, 91.3)   83.3 (80.9, 85.8) -4.9 (-9.7, -0.2) 0.37   92.0 (87.9, 96.1)    -3.7 (-2.5, -9.9) 0.44
   MDI   90.4 (86.6, 94.7)   83.9 (80.4, 87.4)    -6.5 (-13.2, 0.27) 0.65   91.0 (85.3, 96.7)    0.6 (-8.0, 9.4) 1.00
   CSII   83.3 (77.5, 89.2)   80.6 (75.8, 85.4)  -2.7 (-11.9, 6.5) 1.00     92.8 (84.7, 100.8)      9.4 (-2.7, 21.6) 0.19
   From MDI to CSII   91.1 (85.7, 96.5)   85.5 (81.0, 89.9)  -5.7 (-14.1, 2.8) 0.32   92.2 (84.9, 99.5)      1.1 (-9.9, 12.1) 1.00
Data are the mean (95%CI). Mean differences and P-values are based on linear mixed models. BMI: Body mass index; BP: Blood pressure; MDI: Multiple 
daily injections; CSII: Continuous subcutaneous insulin infusion. 
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years of  follow-up and the occurrence of  macrovascu-
lar and microvascular complications, both of  which are 
known to decrease HRQOL[16-18]. However, this finding 
can be explained in part by improved clinical and/or 
metabolic parameters and/or the low number of  pa-
tients who completed follow-up until 2010[19]. Arguing 
against the latter explanation, no change in HRQOL was 
observed after 7 years of  follow-up, with 71.5% of  the 
study sample intact. 
Regarding the impact of  the therapy mode, a decrease 
in both component scores of  the SF-36 and EuroQol-
VAS was observed among patients using MDI. One 
potential explanation for this finding is the relatively high 
scores of  these HRQOL parameters at baseline com-
pared with patients on CSII. Although speculative, this 
observation can be attributed to a relative short diabetes 
duration[7]. 
In a recent Cochrane review, CSII was preferred over 
MDI with respect to HRQOL[11]. In accordance with our 
study, the only study among T1DM adults that used the 
SF-36 questionnaire demonstrated a significant improve-
ment of  the general health and mental health subscale in 
the CSII group compared with stable values in the MDI 
group after 32 wk of  follow-up[20]. The other SF-36 scales, 
including the component scales, remained unaltered. 
In our current study the HRQOL does not differ be-
tween modes of  therapy, but the patient can choose his 
or her mode of  choice in daily practice to a larger extent. 
This observation could partially explain the differences 
found in randomised trials (in favour of  the treatment 
mode under investigation, mainly CSII) and the absence 
of  differences in daily practice. 
Although in many cases inadequate metabolic control 
is the main indication to commence CSII, we did not 
observe any significant difference regarding HbA1c at 
the start of  therapy, HbA1c at final follow-up or changes 
in HbA1c over time between patients on MDI and those 
switching to CSII. Therefore, we conclude that the switch 
to CSII was initiated in some of  the patients for reasons 
other than poor metabolic control. 
Our findings also demonstrate that it is possible in 
daily practice to maintain moderate to good control 
of  clinical parameters in a T1DM population and even 
improve these parameters. The reasons for this improve-
ment remain open for discussion. Organisation of  care, 
stricter guidelines, more education, improved pump and 
pen systems and a more active role of  patients them-
selves may be involved. No definite conclusions can be 
drawn to explain this finding because not all these data 
were recorded in this study. 
Interpretations of  the findings from our study are 
limited by various factors, including the magnitude of  
loss to follow-up during the 15-year study period. There-
fore, the results of  our study should be interpreted with 
caution, and generalisability may be limited. This rate of  
loss to follow-up can be partly explained by the relatively 
young age of  our population and the accompanied high 
relocation rate, which is the reason for approximately half  
of  the loss to follow-up. In addition, 12 patients, mostly 
woman, moved to a hospital nearby after the departure 
of  one of  the diabetologists from our centre. Our results 
are also limited by the lack of  appropriate controls and 
the use of  questionnaires that measure general HRQOL.
In a conclusion, no differences with respect to meta-
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Table 4  Estimated changes in health-related quality of life during follow-up
HRQOL parameters 1995 (A) mean 2002 (B) mean Mean difference (B-A) P -value 2010 (C) mean Mean difference (C-A) P -value
SF-36
   MCS
      All 81.3 (78.9, 83.7) 78.3 (75.6, 81.0)         -3.0 (-7.4, 1.4) 0.31 77.1 (74.2, 80.0)         -4.2 (-8.7, 0.41) 0.09
      MDI  86.8 (83.4, 90.3)a 80.4 (76.5, 84.3)    -6.5 (-12.8, -0.14) 0.04 77.1 (72.9, 81.2) -9.8 (-16.3, -3.2) 0.01
      CSII 78.0 (73.4, 82.6) 77.0 (71.8, 82.3)       -1.00 (-9.5, 7.5) 1.00 76.5 (70.9, 82.1)         -1.6 (-10.4, 7.3) 1.00
      From MDI to CSII 79.0 (74.8, 83.3) 77.5 (72.7, 82.3)         -1.5 (-9.3, 6.3) 1.00 77.9 (72.7, 83.1)         -1.1 (-9.2, 7.0) 1.00
   PCS
      All 84.1 (81.6, 86.5) 81.1 (78.4, 83.8)         -3.0 (-7.5, 1.4) 0.31 79.5 (76.5, 82.4)         -4.6 (-9.3, 0.07) 0.06
      MDI 88.7 (85.1, 92.2) 84.3 (80.3, 88.2) -4.4 (-10.9, 2.0) 0.29 80.1 (75.9, 84.3) -8.6 (-15.3, -1.8) 0.01
      CSII 81.5 (76.7, 86.2) 79.3 (74.2, 84.5) -2.1 (-10.7, 6.5) 1.00 77.8 (72.0, 83.5)         -3.7 (-12.8, 5.4) 0.98
      From MDI to CSII 82.1 (77.7, 86.5) 79.6 (74.8, 84.4) -2.5 (-10.4, 5.4) 1.00 80.5 (75.2, 85.8)         -1.6 (-9.9, 6.8) 1.00
EuroQol
   EuroQol-5D
      All 0.94 (0.92, 0.95) 0.91 (0.89, 0.93) -0.03 (-0.06, 0.01) 0.12 0.94 (0.92, 0.95) 0.00 (0.03, -0.03) 1.00
      MDI 0.96 (0.93, 0.98) 0.92 (0.88, 0.95) -0.4 (-0.9, 0.01) 0.12 0.96 (0.93, 0.98) 0.00 (0.04, -0.04) 1.00
      CSII 0.93 (0.90, 0.97) 0.91 (0.87, 0.95)   0.3 (-0.9, 0.04) 0.98 0.93 (0.90, 0.97) 0.00 (0.06, -0.06) 1.00
      From MDI to CSII 0.92 (0.89, 0.95) 0.90 (0.86, 0.94)   0.02 (-0.08, 0.04) 1.00 0.92 (0.89, 0.95) 0.00 (0.05, -0.05) 1.00
   EuroQol-VAS
      All 83.6 (81.4, 85.9) 76.9 (74.4, 79.5) -6.7 (-10.9, 2.5) 0.01 76.3 (73.8, 78.8) -7.3 (-11.4, -3.3) 0.01
      MDI 86.4 (83.1, 89.7) 78.3 (74.6, 82.0)   -8.1 (-14.1, -2.1) 0.01 78.3 (74.8, 81.8) -8.1 (-14.0, -2.3) 0.01
      CSII 82.9 (78.5, 87.2) 76.4 (71.4, 81.3) -6.5 (-14.5, 1.6) 0.16 73.3 (68.5, 78.1) -9.6 (-17.5, -1.7) 0.01
      From MDI to CSII 81.6 (77.6, 85.6) 76.1 (71.5, 80.6) -5.5 (-12.9, 1.9) 0.22 77.3 (73.0, 81.6)         -4.3 (-11.5, 2.9) 0.45
Data are the mean (95%CI). HRQOL: Health-related quality of life; MDI: Multiple daily injections; CSII: Continuous subcutaneous insulin infusion; MCS: 
Mental component summary; PCS: Physical component summary. Mean differences and P-values are based on linear mixed models. aP < 0.05 at that mo-
ment in time vs the MDI and from MDI to CSII treatment groups.
van Dijk PR et al . Follow-up of HRQOL in T1DM
bolic and HRQOL parameters between the various treat-
ment modalities were observed after 15 years of  follow-
up between patients using MDI or CSII or patients 
switching from MDI to CSII in a setting in which pa-
tients, to a large extent, choose the mode of  therapy that 
best suits them. 
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is unknown.
Research frontiers
As HRQOL and metabolic control are important outcomes of T1DM manage-
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of life scales. The present study is the first to describe the long-term natural 
course of HRQOL among patients with T1DM. In addition, results of the study 
show no differences with respect to HRQOL and metabolic parameters between 
the various treatment modalities after 15 years of follow-up between patients 
using MDI, CSII or patient who switched from MDI to CSII.
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The results of this study show that HRQOL and metabolic control is stable 
among T1DM patients. In addition, there is no impact of the mode of insulin 
therapy on HRQOL. Therefore, the findings of this study supports clinical deci-
sion making.
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CSII: continuous subcutaneous insulin infusion, insulin is administered continu-
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injections, insulin is administered in the SC tissue using injections.
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